Resumen

APARICIO HERNANDEZ, R.; GARCIA LUQUE, A.; SANCHEZ LOPEZ, P.  y  PRATS OLIVAN, P.. Possitive assesment of drugs: March, April and May 2019. Sanid. Mil. [online]. 2019, vol.75, n.3, pp.156-161.  Epub 20-Ene-2020. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712019000300005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2018, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palabras clave : Arginina/lisina, Lysakare ^®; Avatrombopag, Doptelet^®; Buprenorfina, Sixmo^®; Células autólogas CD34+ codificantes del gen βA-T87Q-globina, Zynteglo^®; Cemiplimab, Libtayo^®; Dihidrocloruro de trientina, Cufence^®; Dolutegravir/Lamivudina, Dovato^®; Hidroxicarbamida, Xromi^®; Pegfilgrastim, Grasustek^®; Ravulizumab, Ultomiris^®; Talazoparib, Talzenna^®; Toxina botulínica tipo A, Nuceiva^®; Turoctocog alfa pegol Esperoct^®.

        · resumen en Español     · texto en Español     · Español ( pdf )